Bivatuzumab (Anti-CD44v6)
Bivatuzumab (Anti-CD44v6) is a humanized monoclonal antibody targeting against CD44v6 that could acts as a sarcoma target for CAR-redirected CIK cells. MW:145.5 KD.
Supplier | Selleck Chemicals |
---|---|
Product # | A2555 |
Sku # | A2555-1mg*25 |
Pricing | 1mg*25, $2370.00 |